Search International and National Patent Collections

1. (WO1998050051) TREATMENT OF SICKLE CELL DISEASE, TREATMENT OF IMMUNE SYSTEM DISEASES AND OTHER DISEASES NORMALLY ASSOCIATED WITH SICKLE CELL ANEMIA

Pub. No.:    WO/1998/050051    International Application No.:    PCT/US1997/007122
Publication Date: Fri Nov 13 00:59:59 CET 1998 International Filing Date: Tue May 06 01:59:59 CEST 1997
IPC: A61K 31/07
A61K 31/34
A61K 31/355
A61K 31/44
A61K 31/51
A61K 31/70
A61K 33/04
A61K 33/06
A61K 33/24
A61K 33/32
A61K 33/36
Applicants: LOCKETT, Curtis
Inventors: LOCKETT, Curtis
Title: TREATMENT OF SICKLE CELL DISEASE, TREATMENT OF IMMUNE SYSTEM DISEASES AND OTHER DISEASES NORMALLY ASSOCIATED WITH SICKLE CELL ANEMIA
Abstract:
A maintenance regimen with controlled intake of particular vitamin, mineral, and micronutrient formulations, drastically reduces the incidence and severity of sickle cell disease crises. The formulations include vitamin A, vitamin B-1, vitamin B-2, vitamin B-6, vitamin B-12, vitamin C, vitamin D, vitamin E, niacinamide, para-aminobanzoic acid (PABA), pantothenic acid, choline bitartrate, inosital, rutin, citrus bioflavonoid complex, betaine hydrochloride, hesperidin complex, folic acid, biotin, calcium, iron, magnesium, zinc, potassium, manganese, iodine, chromium, selenium, and a pharmaceutically acceptable carrier, provided at or just below critical saturation levels, determined for each individual by carefully monitoring tolerance on titration. The daily dose may exceed that necessary as dietary or nutritional supplements, and trigger an increase in the production of viable hemoglobin, and alters the overall blood profile. Platelet concentration is increased up to twice that seen in normal blood, and the red blood cells produced display increased resistance to sickling. This enhanced biosynthesis is achieved by providing sufficient stores of precursors that stimulate low level manufacture without substantial feedback control by the upper central nervous system.